Dilated cardiomyopathy in the course of thrombophilia
More details
Hide details
Department of Internal Medicine, Medical University, Lublin, Poland
Student Scientific Society, Medical University, Lublin, Poland
Andrzej Prystupa   

Department of Internal Medicine, Medical University, Lublin, Staszica 16, 20-081 Lublin, Poland.
J Pre Clin Clin Res. 2010;4(2):165–167
A 40-year-old patient with diagnosed thrombophilia was admitted to the Department due to symptoms suggestive of pulmonary embolism. The imaging results excluded pulmonary embolism; echocardiography revealed dilated cardiomyopathy. The report discusses the association between thrombophilia and possible development of cardiomyopathy.
Dec GW, Fuster V: Idiopathic dilated cardiomyopathy. N Engl J Med 1994, 331, 1564-1575.
Hershberger RE, Kushner JD, Parks SB: Dilated cardiomyopathy overview. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. Gene Reviews [Internet]. Seattle (WA): University of Washington, Seattle, 2008.
Pankuweit S, Richter A, Ruppert V, Maisch B: Familial predisposition and microbial etiology in dilated cardiomyopathy. Herz 2009, 34, 110- 116.
Ng T, Brown JR, Edmondson RA, Tillyer ML: Catastrophic arterial thromboembolism associated with factor V Leiden. Eur J Vasc Endovasc Surg 2000, 19, 551-553.
Mandegar MH, Saidi B, Roshanali F: Extensive arterial thrombosis in a patient with factor V Leiden mutation. Interact Cardiovasc Thorac Surg 2010, 11, 127-129.
Dönmez Y, Kanadasi M, Tanrıverdi K, Demir M, Demirtas M, Cayli M, Alhan C, Baslamisli F: Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. Jpn Heart J 2004, 45, 505-512.
Glueck CJ, Munjal J, Aregawi D, Agloria M, Winiarska M, Khalil Q, Wang P: Thrombophilia-hypofibrinolysis and atherothrombotic cardiovascular disease < or = age 45 years. Transl Res 2007, 150, 93-100.
Bock S, Harris J, Balazs I, Trent J: Assignment of the human antithrombin III structural gene to chromosome 1q23-25. Cytogenet Cell Gene 1985, 39, 67-69.
Lane D, Bayston T, Olds R, Fitches AC, Cooper DN, Millar DS, Jochmans K, Perry DJ, Okajima K, Thein SL, Emmerich J: Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997, 77, 197-211.
Fujimori Y, Okimatsu H, Kashiwagi T, Sanda N, Okumura K, Takagi A, Nagata K, Murate T, Uchida A, Node K, Saito H, Kojima T: Molecular defects associated with antithrombin deficiency and dilated cardiomyopathy in a Japanese patient. Inter Med 2008, 47, 925-931.
De Stafano V, Chiusolo P, Paciaroni K, Leone G: Epidemiology of factor V Leiden: clinical implications. Semin Hemostas 1998, 24, 367-379.
Morton KE, Gavaghan TP, Krilis SA, Daggard GE, Baron DW, Hickie JB, Chesterman CN: Coronary artery bypass graft failure – an autoimmune phenomenon. Lancet 1987, 2, 977-978.
Brown JH, Doherty CC, Allen DC, Morton P: Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus. Br Med J 1988, 296, 1505.
Doggen CJM, Cats VM, Bertina RM, Rosendaal FR: Interaction of coagulation defects and cardiovascular risk factors. Increased risk of myocardial infarction associated with factor V Leiden or prothrombin G20210A. Circulation 1998, 97, 1037-1041.
Van de Water NS, French JK, Lund M, Hyde TA, White HD, Browett PJ: Prevalence of factor V Leiden and prothrombin variant G20210A in patients age < 50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol 2000, 36, 717-722.